Literature DB >> 27790131

Primary Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue of the Lacrimal Sac Found with Epiphora: A Case Report.

Yoshiyuki Kitaguchi1, Yasuhiro Takahashi1, Jacqueline Mupas-Uy1, Emiko Takahashi2, Hirohiko Kakizaki1.   

Abstract

We report a case of a primary marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue of the lacrimal sac, which was found in a patient with epiphora without palpable mass. Magnetic resonance imaging demonstrated mucosal thickening of the lacrimal sac with a patent lumen, consistent with the intraoperative finding. Epiphora resolved, which was confirmed by smooth syringing, 1 month after starting the immunotherapy.

Entities:  

Keywords:  Epiphora; Immunotherapy; Lacrimal sac; MALT lymphoma; Magnetic resonance imaging

Year:  2016        PMID: 27790131      PMCID: PMC5073679          DOI: 10.1159/000449121

Source DB:  PubMed          Journal:  Case Rep Ophthalmol        ISSN: 1663-2699


Introduction

Marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) of the lacrimal sac is a quite rare cause of the lacrimal duct obstruction [1, 2]. Typically, this entity initially presents with epiphora, followed by dacryocystitis and/or a palpable mass [3]. A lack of specific symptoms may result in difficult diagnosis, which delays decision for biopsy. Concomitant dacryocystitis also interferes in the palpation of mass [3]. Lacrimal sac tumors are more exposed to inflammatory conditions compared to other ocular adnexal disorders [4]. MALT lymphoma may transform into a more aggressive subtype like diffuse large B cell lymphoma [4]. This suggests the importance of early diagnosis of lacrimal sac lymphomas. The clinical features of primary MALT lymphoma of the lacrimal sac have not been well documented. We report a case of this entity found in a patient who presented merely with epiphora.

Case Report

A 38-year-old woman was referred due to an incidental finding of a mass in her right lacrimal sac on computed tomography (CT) for a subcutaneous tumor of the cheek. She had an epiphora for 2 months. There was no history of dacryocystitis, pain or swelling in this region. The tumor was not palpable even with compression. She was otherwise healthy and without any medications. The CT image showed a mass in her right lacrimal sac without bony erosion (fig 1a). Magnetic resonance imaging (MRI) revealed slight hyperintensity on T1-weighted and T2-weighted images of the extraocular muscles, with homogenous contrast enhancement (fig 1b–e). The lumen appeared to be patent with low intensity on T1- but bright on T2-weighted images (fig 1c–e).
Fig. 1

Lymphoma of right lacrimal sac (arrows). a The CT scan showed a high-density mass without bony erosion. T1-weighted (b) and T2-weighted (c) axial images. Postcontrast T1-weighted axial (d) and coronal (e) images. Fluid in the lacrimal sac appeared as hyperintensity on T2-weighted, and as hypointensity on postcontrast T1-enhanced images (arrowheads).

She underwent transcutaneous incisional biopsy. The outer wall of the lacrimal sac showed normal appearance. When the sac wall was opened, the lacrimal sac mucosa was markedly thickened with a patent lumen (fig 2). Pinkish gray mucosa was noticed, and it was removed for histopathological examination. The lacrimal sac was closed by interrupted sutures using 6-0 polyglycolide (Vsorb; Kono Seisakusho Co., Ltd., Tokyo, Japan).
Fig. 2

Intraoperative finding. The mucosal wall of the lacrimal sac is markedly thickened with a patent lumen.

The histopathological examination revealed diffuse infiltration of small round to cleaved lymphocytes, consistent with MALT lymphoma (fig 3a, b). On immunohistochemistry, the tumor cells were positive for CD20, and CD79a, but negative for bcl-2, CD3, CD5, CD10, CD23, cyclin-D1, and bcl-6 (fig 3c, d). MIB-1-positive cells were present in 10% of all cells. Kappa to lambda was >1.0. Thus, the histological findings supported the diagnosis. Systemic evaluation revealed no occurrence of lymphoma in other areas. Her epiphora resolved, with a patent nasolacrimal duct irrigation 1 month after starting rituximab monotherapy.
Fig. 3

Infiltration of small round to cleaved lymphocytes in the specimen from the lacrimal sac mucosa. a HE. ×40. b HE. ×400. Staining with an immunohistochemical marker of CD20 (original magnification ×200) (c), and CD79a (original magnification ×200) (d), consistent with the diagnosis of marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue.

Discussion

We reported a rare case of a primary MALT lymphoma of the lacrimal sac and documented clinical features in detail. As the lacrimal sac contains lacrimal drainage-associated lymphoid tissue which constitutes part of the mucosa-associated lymphoid tissue [5], MALT lymphoma may arise in the lacrimal sac. In fact, it is the commonest subtype occupying one third of all primary lacrimal sac lymphomas [6]. However, the clinical characteristics of this subtype are not fully known because only 8 cases have been reported in the English literature (table 1) [2, 6, 7, 8].
Table 1

Our case and 8 reported cases of primary lacrimal sac MALT lymphoma

CaseSourceDiagnosisAge, yearsSexSymptomsTreatmentFollow-up (months)
1Schefler et al. [2]MALT10MEpiphora (1 week), painful swelling (3 weeks)Dacryocystorhinostomy CHOP×2Alive (30)
2Sjo et al. [6]MALT93MEpiphora, swellingIncomplete excision Refused further treatmentAlive (12)
3Sjo et al. [6]MALT71MEpiphora (over 6 months), swellingRT + CHOP×6Relapse LN and BM (8), dead, cause unknown (120)
4Sjo et al. [6]MALT71FEpiphora, swellingRT 45 GyAlive (144)
5Parmar and Rose [7]MALT81FEpiphora (4 months), sac and canalicular massChlorambucilAlive (36)
6Parmar and Rose [7]MALT56MEpiphora (2 months), inner canthal massRT DacryocystorhinostomyAlive (46)
7Parmar and Rose [7]MALT50FEpiphora (6 months), inner canthal massRTAlive (16)
8Kheterpal et al. [8]MALT82FEpiphora (1 year), swelling, recurrent dacryocystitisRTAlive (6)
9This caseMALT38FEpiphoraRituximabAlive (3)

LN = Lymph node; BM = bone marrow; RT = radiation therapy; CHOP = cyclophosphamide + doxorubicin + vincristine + prednisone.

Epiphora with a swollen lacrimal sac wall is a diagnostic sign of a lacrimal sac tumor [3]. However, epiphora precedes tumor palpation for several months in lacrimal sac MALT lymphoma [2, 3, 6, 7, 8]. Diagnosis of a lacrimal sac tumor is difficult without palpation, as epiphora is a nonspecific symptom which is also present in acquired nasolacrimal duct obstruction. Therefore, we need to include lacrimal sac tumor in the differential diagnosis in cases of epiphora with successful lacrimal syringing [3]. MRI is useful for qualitative diagnosis of the lesion. In this case, it also demonstrated a typical finding of ocular adnexal lymphoma to extraocular muscles as a slight hyperintensity on T1-weighted and T2-weighted images [9]. Fluid intensity in the center of the sac represented the patent lumen, which was consistent with intraoperative findings. As radiotherapy, chemotherapy and immunotherapy are effective in the treatment of lacrimal sac MALT lymphoma [2, 6, 7, 8], surgery should be limited to biopsy in order to avoid surgical complications. An exact preoperative diagnosis is necessary for proper surgical plan. Intraoperative findings showed a thickened, pinkish gray mucosa that is typical for lacrimal sac lymphoma [2]. The pathological mucosa with a healthy outer wall suggested that the MALT lymphoma extended into the sac cavity first and outside of the wall next. This extending manner was consistent with the fact that the mucosa-associated lymphoid tissue localizes in the adenoid layer of the mucosa beneath the epithelial lining [10]. A lacrimal pump system failure resulting in epiphora was likely due to denatured sac mucosa despite of patent lumen macroscopically. Chronic dacryocystitis needs to be differentiated from lacrimal sac MALT lymphoma. Chronic dacryocystitis occasionally demonstrates a nodular lymphoid infiltration pattern in subepithelial and intraepithelial areas, mimicking MALT lymphoma [11]. However, chronic dacryocystitis mostly shows diffuse infiltration pattern [12]. Increased goblet cell density and hyperplastic mucosal glands in cases with chronic dacryocystitis are also helpful for differential diagnosis [12]. In addition, the presence of round to cleaved centrocyte-like cells and positive immunoglobulin light chain (kappa or lambda) supported the diagnosis of MALT lymphoma in this case [13]. Lacrimal duct obstruction remains persistent in most reported cases despite regression of lymphomas after radiation and/or chemotherapy [1]. However, smooth lacrimal duct irrigation was noted in the present case. This could be due to incomplete obstruction of the lacrimal sac at the time of diagnosis. In addition, incisional biopsy by opening the sac did not result in secondary stenosis. Although radiotherapy was used in most reported cases [6, 7, 8], this treatment often induces lacrimal gland dysfunction, resulting in dry eyes [2, 14]. We preferred rituximab immunotherapy to avoid this complication. In summary, we reported a rare case of a lacrimal sac MALT lymphoma found on epiphora without palpable mass. MRI was helpful in the qualitative diagnosis of this tumor. Diagnosis of this case before developing total obstruction resulted in successful preservation of the lacrimal drainage function.

Statement of Ethics

This study was approved by the Ethics Committee of Aichi Medical University Hospital and adhered to the tenets of the 1964 Declaration of Helsinki.

Disclosure Statement

The authors have no competing interests to declare.
  13 in total

1.  Lacrimal sac lymphoma in a child.

Authors:  Amy C Schefler; Carol L Shields; Jerry A Shields; Hakan Demirci; Marlon Maus; Ralph C Eagle
Journal:  Arch Ophthalmol       Date:  2003-09

2.  Tumors of the lacrimal sac.

Authors:  I S JONES
Journal:  Am J Ophthalmol       Date:  1956-10       Impact factor: 5.258

3.  Low-grade systemic lymphoma with aggressive transformation in the lacrimal sac.

Authors:  N M Peter; R Khooshabeh
Journal:  Eye (Lond)       Date:  2012-03-02       Impact factor: 3.775

Review 4.  Serum free light chain analysis.

Authors:  Matthew S Davids; Mandakolathur R Murali; David J Kuter
Journal:  Am J Hematol       Date:  2010-10       Impact factor: 10.047

5.  Previously undiagnosed lymphoma presenting as recurrent dacryocystitis.

Authors:  S Kheterpal; S Y Chan; A Batch; G R Kirkby
Journal:  Arch Ophthalmol       Date:  1994-04

Review 6.  Mucosa-associated lymphoid tissue (MALT) lymphoma: a practical guide for pathologists.

Authors:  Chris M Bacon; Ming-Qing Du; Ahmet Dogan
Journal:  J Clin Pathol       Date:  2006-09-01       Impact factor: 3.411

7.  Ophthalmologic outcomes after chemotherapy and/or radiotherapy in non-conjunctival ocular adnexal MALT lymphoma.

Authors:  Ji-Sun Paik; Won-Kyung Cho; Sung-Eun Lee; Byung-Ock Choi; Seung-Eun Jung; Gyeong-Sin Park; Sung-Hoon Kim; Suk-Woo Yang; Seok-Goo Cho
Journal:  Ann Hematol       Date:  2012-04-29       Impact factor: 3.673

8.  Primary lymphoma of the lacrimal sac: an EORTC ophthalmic oncology task force study.

Authors:  L D Sjö; E Ralfkiaer; B R Juhl; J U Prause; T Kivelä; C Auw-Haedrich; F Bacin; M Carrera; S E Coupland; B Delbosc; N Ducrey; B Kantelip; J L Kemeny; P Meyer; N C Sjö; S Heegaard
Journal:  Br J Ophthalmol       Date:  2006-05-03       Impact factor: 4.638

Review 9.  Primary non-Hodgkin's lymphoma of the lacrimal sac: a case report and a review of the literature.

Authors:  K Nakamura; S Uehara; J Omagari; N Kunitake; M Kimura; Y Makino; K Ishigami; K Masuda
Journal:  Cancer       Date:  1997-12-01       Impact factor: 6.860

10.  Management of lacrimal sac tumours.

Authors:  D N Parmar; G E Rose
Journal:  Eye (Lond)       Date:  2003-07       Impact factor: 3.775

View more
  1 in total

1.  Diffuse Large B-Cell Lymphoma of the Lacrimal Sac in a Japanese Patient.

Authors:  Satoshi Kakutani; Yasuhiro Takahashi; Ma Regina Paula Valencia; Hirohiko Kakizaki
Journal:  Case Rep Ophthalmol       Date:  2019-01-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.